Login
NovoCure Ltd logo

NovoCure Ltd

novocure.com

What Do They Do?

Sells wearable medical devices that deliver Tumor Treating Fields therapy to patients with glioblastoma, lung cancer and pancreatic cancer.

Who Are Their Customers?

Patients use NovoCure’s products in active markets; the company has coverage policies with public and private payers for Optune Gio and seeks case-by-case reimbursement for Optune Lua and Optune Pax where broader coverage is being pursued. Zai Lab has a license to commercialize the products in Greater China.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +16%
vs $167.2M in Q3 FY2025
Net income
▲ +72% (Loss)
vs −$37.3M in Q3 FY2025
  • Nov 9, 2026 FDA declined approval of Optune Mya for brain metastases
  • Oct 29, 2026 NovoCure raised 2026 revenue and adjusted EBITDA guidance
  • Oct 1, 2026 Japan approved Optune Pax for locally advanced pancreatic cancer
  • Jun 30, 2026 Optune Pax received a CE Mark for locally advanced pancreatic cancer

More cancer uses The latest report describes Optune Lua for non-small cell lung cancer and Optune Pax for pancreatic cancer; the older report described Optune Lua for mesothelioma and reported lung cancer as a clinical-study area.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support